Eptinezumab Reduces Migraines Over Long-Term PROMISE 1 ResultsApril 24th 2018
Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.
Novel Non-Invasive Remedy for Cluster HeadacheMay 5th 2017
Peter Goadsby, M.B., B.S., Director of the NIHR- Wellcome Trust Kingâ€™s Clinical Research, London, Professor of Neurology, University of California at San Francisco, explained the benefits of the recent FDA approval of the gammaCore non-invasive vagal nerve stimulator on patients suffering from cluster headaches.
Epilepsy: Novel Approaches to TreatmentMay 4th 2017
Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine addressed that there were several medications in the pipeline being tested for different aspects of epilepsy treatment.
Diabetes: Transforming Technology into Safe and Effective MedicinesMay 3rd 2017
Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their teamâ€™s programs in type 2 diabetes. One is an activator of an enzyme called glucocynase â€“ a master regulator for glucose in the body. According to Altstiel, when glucose is too high, it either shuns it off to energy production or stores it in the form of glycogen. Itâ€™s an insulin independent way of how the body controls glucose.